January 19, 2024 8:48am

The difference between 'will' and 'would' is that 'will' is used in statements that refer to the future while 'would' is used to refer to events of the future in past tense

Thursday’s close indicated a very weak aftermarket, when will the sector prepare to TURN?

News: AxoGen (AXGN +$0.14 aftermarket indication) announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05). Mesoblast (MESO) FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) … https://www.regmedinvestors.com/articles/13292

Pre-open Indications: 4 Positive and 1 Negative Indications

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What RMi provides is a trusted source of share pricing intelligence. Join me … in the NO spin zone!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progression.

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Friday: The pre-open Dow futures are +0.55% or (+208 points), the S&P futures are UP +0.57% or (+27 points) as the Nasdaq futures are UP +136 or 0.80% (points)

Stock futures jumped Friday,

European stock markets extended gains,

Asia-Pacific market all rose and surged

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday: Indexes closed positive, as benchmark Treasury yields moved higher after robust U.S. labor market data weakened bets that the Fed would begin lowering as the Dow closed UP +201.94 points or +0.54%, the S&P closed UP +41.73 points or +0.88% while the Nasdaq closed UP +200.03 points or +1.35%

For the week so far, the Nasdaq advanced +0.55%, the Dow is down -0.33% while the S&P 500 is y -0.06% lower.

Economic Data Docket: December’s existing home sales reading; also, preliminary consumer sentiment data

  • Thursday, the Philadelphia Fed manufacturing index inched up to -10.6 in January from the previous month's revised reading of -12.8. It had been expected to improve to -6.7. However, this was not as weak as the Empire State Index data released earlier in the week.

 

Wednesday, RegMed Investors (RMi) Closing Bell: “cell and gene therapy sector loses muscle strength while clinging to newest bottoms” … https://www.regmedinvestors.com/articles/13291

 

Q1/24: 2 holidays, 9 negative and 3 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Thursday, Wednesday, Tuesday, Monday’s holiday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

AxoGen (AXGN) closed up +$0.33 with a positive +$0.14 or +1.72% pre-open indication having announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05).

Beam Therapeutics (BEAM) closed down -$0.67 after Wednesday’s -$0.97 after Tuesday’s -$0.50 with a positive +$0.29 or +1.24% pre-open indication

Mesoblast (MESO) closed 1/18 down -$0.02 with a positive +$0.15 or +8,72% aftermarket indication on new … https://www.regmedinvestors.com/articles/13292

Intellia Therapeutics (NTLA) closed down -$0.50 after Wednesday’s -$1.02 and Tuesday’s -$0.91 with a positive $0.42 or +1.66% pre-open indication

 

Negative Indications:

Thursday, Wednesday, Tuesday, Monday’s holiday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Verve Therapeutics (VERV) closed down -$0.06 after Thursday’s -$0.16 with a negative -$0.22 or -1.79% pre-open indication.

 

The BOTTOM LINE: the cell and gene therapy sector has given-up some serious value and closed-off Thursday with the newest lows.

  • Thursday’s close had a very weak aftermarket, the sector should be preparing to TURN!
  • Remember, buying opportunities will appear when the market is on a short-term upswing, only for those sector equities to fall back when the indexes fade.

 It’s now the end of the 3nd week of 2024, we have eaten more value that even almost exceeded the last months of 2023.

  • Thursday closed negative with 10 incliners, 25 decliners and 0 flat
  • Wednesday closed negative with 6 incliners, 29 decliners and 0 flat
  • (1/16) Tuesday closed negative with 8 incliners, 25 decliners and 1 flat
  • Monday was market holiday
  • (1/12) Friday closed negative with 13 incliners, 21 decliners and 1 flat
  • Thursday closed negative with 8 incliners, 26 decliners and 1 flat
  • Wednesday closed negative with 14 incliners, 21 decliners and 0 flat
  • Tuesday closed negative with 14 incliners, 18 decliners and 3 flats
  • (1/8) Monday closed positive with 28 incliners, 6 decliners and 1 flat
  • Friday closed negative with 12 incliners, 23 decliners and 0 flat
  • Thursday closed positive with 22 incliners, 12 decliners and 1 flat
  • Wednesday closed negative with 6 incliners, 29 decliners and 0 flat
  • (1/2) Tuesday closed positive with 21 incliners, 14 decliners and 0 flat

 

Coming attractions …Q4 and FY23 reporting season and “runways” will get measured as consensus and estimates will get missed!

  • During the session, the 10-year Treasury yield topped 4.119%.

 

For the next few weeks, if you're buying on weakness, you might be jumping onto a sinking ship even as … Q4 and FY23 earnings LPS (loss-per-share) are due even though some highlights were delivered to facilitate JPM presentations – there are consensus and beaten estimates to be reckoned!

 

Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's also a good idea to take some profits, especially if you didn't do so in past sessions. <IBD>

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.